Compounds > fluorodeoxyglucose f18
Page last updated: 2024-08-24

fluorodeoxyglucose f18 and ER-Negative PR-Negative HER2-Negative Breast Cancer

fluorodeoxyglucose f18 has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 47 studies

Research

Studies (47)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's28 (59.57)24.3611
2020's19 (40.43)2.80

Authors

AuthorsStudies
Choi, YJ; Kang, T; Kim, H; Kim, IJ; Kim, K; Pak, K; Seol, YM1
Dong, Z; Kotagiri, N; Mahoney, M; Singaravelu, I; Spitz, H1
Gong, C; Hu, S; Hu, X; Li, Y; Liu, C; Song, S; Wang, B; Xie, Y; Yang, Z; Zhao, Y1
Bhoriwal, S; Ephraim, R; Kar, M; Muduly, DK; Pathak, M; Ray, S; Sultania, M1
Erdil, TY; Filizoglu, N; Ozguven, S1
Cheon, GJ; Choi, H; Han, W; Kang, KW; Lee, HB; Lee, R; Paeng, JC; Seok, JW; Whi, W1
Arihiro, K; Emi, A; Kadoya, T; Kimura, Y; Masumoto, N; Okada, M; Sasada, S1
Cao, G; Fan, H; Liu, Y; Shao, W; Shi, X; Wang, W; Zhang, J1
Chae, SY; Gong, G; Han, S; Lee, J; Lee, SB; Moon, DH; Oh, JS1
Akbas, S; Arslan, E; Battal Havare, S; Beyhan, E; Can Trabulus, FD; Cin, M; Ergül, N; Erol Fenercioglu, Ö; Fikret Çermik, T; Mermut, Ö; Sahin, R1
Huang, G; Liu, J; Meng, H; Wang, C; Wen, J; Zhao, H1
Fettig, N; Li, S; Luo, J; Prmeau, T; Roy, S; Savaikar, MA; Shoghi, KI; Strong, L; Wahl, RL; Whitehead, T1
Deng, S; He, Y; Liu, H; Liu, S; Sun, H; Weng, Z; Yang, J; Zhang, B; Zuo, B1
Laffon, E; Marthan, R1
Jeong, WG; Ki, SY; Kwon, SY; Lee, HJ; Lee, JE; Lee, JS; Lim, HS; Park, HM; Park, MH; Shin, SS1
De Meulenaere, V; De Wever, O; Deblaere, K; Descamps, B; Vanhove, C1
Gao, Q; Li, X; Liu, J; Wang, Z; Xia, Y; Xu, T1
Ademuyiwa, FO; Dehdashti, F; Li, S; Roy, S; Shoghi, KI; Wahl, RL; Whitehead, TD1
Aime, S; Anemone, A; Bracesco, M; Capozza, M; Della Peruta, M; Dhakan, C; Longo, DL; Terreno, E; Villano, D; Zullino, S1
Gilhuijs, KG; Koolen, BB; Pengel, KE; Rodenhuis, S; Rutgers, EJ; Sonke, GS; Teixeira, SC; Valdés Olmos, RA; van Ramshorst, MS; Vogel, WV; Vrancken Peeters, MT; Wesseling, J1
Cheon, GJ; Chung, JK; Kang, KW; Kim, YI; Kim, YJ; Lee, DS; Paeng, JC1
Abdel-Atti, D; Dilling, TR; Edwards, KJ; Evans, MJ; Henry, KE; Lewis, JS1
Akimoto, E; Emi, A; Kadoya, T; Kajitani, K; Masumoto, N; Ohara, M; Okada, M; Shigematsu, H1
Drude, N; Miran, T; Morgenroth, A; Mottaghy, FM; Vogg, ATJ1
Hanaoka, H; Kartamihardja, AAP; Nakajima, T; Nguyen-Cong, T; Nguyen-Thu, H; Tsushima, Y; Yamaguchi, A1
Bertheau, P; Biard, L; Bouhidel, FA; de Cremoux, P; Espié, M; Groheux, D; Lehmann-Che, J; Merlet, P; Poirot, B; Resche-Rigon, M; Sotiriou, C; Teixeira, L1
Groheux, D1
Belloli, S; Bogni, A; Bombardieri, E; Daidone, MG; Moresco, RM; Pascali, C; Presotto, L; Raccagni, I; Russo, G; Stefano, A; Tortoreto, M; Valtorta, S; Zaffaroni, N1
Choi, BB; Kim, KH; Lee, JS1
Brunotte, F; Cochet, A; Coutant, C; Grapin, M; Humbert, O; Ladoire, S; Riedinger, JM1
Gilhuijs, KG; Koolen, BB; Pengel, KE; Rodenhuis, S; Rutgers, EJ; Valdés Olmos, RA; Vincent, AD; Vogel, WV; Vrancken Peeters, MJ; Wesseling, J2
Emi, A; Kadoya, T; Masumoto, N; Ohara, M; Okada, M; Ozaki, S; Shigematsu, H; Tsutani, Y1
Engebråten, O; Kristian, A; Malinen, E; Mælandsmo, GM; Qu, H; Revheim, ME; Seierstad, T1
Kataoka, M; Kiyoto, S; Mochizuki, T; Nakajima, N; Ochi, T; Ohsumi, S; Sugawara, Y1
Bae, MS; Chang, JM; Cho, N; Kang, KW; Kim, JY; Kim, MY; Kim, WH; Koo, HR; Lee, SH; Moon, WK; Park, JS; Seo, M1
Boubaya, M; Buvat, I; Eder, V; Orlhac, F; Soussan, M; Zelek, L; Ziol, M1
Berger, F; de Cremoux, P; de Roquancourt, A; Espié, M; Giacchetti, S; Groheux, D; Hamy, AS; Hatt, M; Hindié, E; Marty, M; Merlet, P1
Han, W; Kang, KW; Koo, HR; Moon, WK; Park, IA; Park, JS1
Semiglazov, V1
Berriolo-Riedinger, A; Brunotte, F; Charon-Barra, C; Cochet, A; Coutant, C; Desmoulins, I; Fumoleau, P; Humbert, O; Kanoun, S; Lorgis, V; Riedinger, JM1
Kristian, A; Malinen, E; Pitman, KE; Rusten, E1
Audeh, W; Bose, S; Cui, X; Fraass, B; Yue, Y; Zhang, X1
Biard, L; Cuvier, C; de Cremoux, P; de Roquancourt, A; Espié, M; Giacchetti, S; Groheux, D; Hindié, E; Merlet, P; Resche-Rigon, M; Teixeira, L; Vercellino, L1
Berriolo-Riedinger, A; Brunotte, F; Cochet, A; Depardon, E; Dygai-Cochet, I; Fumoleau, P; Humbert, O; Kanoun, S; Lassere, M; Riedinger, JM; Tisserand, S; Toubeau, M; Vrigneaud, JM1
Castillo, R; Goldman, DA; Gönen, M; Jochelson, MS; Pinker-Domenig, K; Riedl, CC; Ulaner, GA; Wills, J1
Bach-Gansmo, T; Bogsrud, TV; Grad, I; Haraldsen, I; Munthe, E; Riss, PJ; Saga, TA1

Trials

2 trial(s) available for fluorodeoxyglucose f18 and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer.
    European journal of nuclear medicine and molecular imaging, 2022, Volume: 49, Issue:2

    Topics: Bayes Theorem; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron-Emission Tomography; Reproducibility of Results; Triple Negative Breast Neoplasms

2022
18F-FDG PET-Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast Cancer.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016, Volume: 57, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Angiography; Antineoplastic Agents; Blood Flow Velocity; Chemotherapy, Adjuvant; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoadjuvant Therapy; Neovascularization, Pathologic; Outcome Assessment, Health Care; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome; Triple Negative Breast Neoplasms

2016

Other Studies

45 other study(ies) available for fluorodeoxyglucose f18 and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
Prognostic value of metabolic activity of the psoas muscle evaluated by preoperative
    BMC cancer, 2021, Oct-27, Volume: 21, Issue:1

    Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Ductal, Breast; Cross-Sectional Studies; Female; Fluorodeoxyglucose F18; Humans; Insulin Resistance; Liver; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Preoperative Care; Prognosis; Proportional Hazards Models; Psoas Muscles; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome; Triple Negative Breast Neoplasms

2021
Antiandrogen Therapy Radiosensitizes Androgen Receptor-Positive Cancers to
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022, Volume: 63, Issue:8

    Topics: Androgen Antagonists; Animals; Cell Line, Tumor; Fluorodeoxyglucose F18; Humans; Mice; Nitriles; Radiation-Sensitizing Agents; Receptors, Androgen; Triple Negative Breast Neoplasms; Ultraviolet Rays

2022
Heterogeneity derived from
    Cancer medicine, 2022, Volume: 11, Issue:9

    Topics: Fluorodeoxyglucose F18; Humans; Immunotherapy; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Triple Negative Breast Neoplasms

2022
Correlation of 18-fluorodeoxyglucose uptake values on PET-CT scan with histological prognostic markers in breast cancer.
    Asia-Pacific journal of clinical oncology, 2023, Volume: 19, Issue:2

    Topics: Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Triple Negative Breast Neoplasms

2023
18F-FDG PET/CT Metabolic Response With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent 4/6 Kinase Inhibitors.
    Clinical nuclear medicine, 2022, Sep-01, Volume: 47, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclins; Female; Fluorodeoxyglucose F18; Humans; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Receptor, ErbB-2; Triple Negative Breast Neoplasms

2022
Association of androgen receptor expression with glucose metabolic features in triple-negative breast cancer.
    PloS one, 2022, Volume: 17, Issue:9

    Topics: Androgens; Female; Fluorodeoxyglucose F18; Gene Expression; Glucose; Humans; Prognosis; Receptors, Androgen; Retrospective Studies; Triple Negative Breast Neoplasms

2022
    Anticancer research, 2023, Volume: 43, Issue:1

    Topics: B7-H1 Antigen; Fluorodeoxyglucose F18; Forkhead Transcription Factors; Humans; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Programmed Cell Death 1 Receptor; Triple Negative Breast Neoplasms; Tumor Microenvironment

2023
Prediction of Clinical Molecular Typing of Breast Invasive Ductal Carcinoma Using
    Academic radiology, 2023, Volume: 30 Suppl 2

    Topics: Breast Neoplasms; Carcinoma, Ductal; Carcinoma, Ductal, Breast; Female; Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Triple Negative Breast Neoplasms

2023
Prognostic significance of pretreatment
    Breast cancer research and treatment, 2023, Volume: 198, Issue:2

    Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Female; Fluorodeoxyglucose F18; Humans; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Receptor, ErbB-2; Retrospective Studies; Triple Negative Breast Neoplasms

2023
The roles of 68 Ga-PSMA PET/CT and 18 F-FDG PET/CT imaging in patients with triple-negative breast cancer and the association of tissue PSMA and claudin 1, 4, and 7 levels with PET findings.
    Nuclear medicine communications, 2023, Apr-01, Volume: 44, Issue:4

    Topics: Claudin-1; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Lymphatic Metastasis; Male; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms; Tomography, X-Ray Computed; Triple Negative Breast Neoplasms

2023
Noninvasive Classification of Human Triple Negative Breast Cancer by PET Imaging with GRP78-Targeted Molecular Probe [
    Molecular imaging and biology, 2020, Volume: 22, Issue:3

    Topics: Animals; Cell Line, Tumor; Endoplasmic Reticulum Chaperone BiP; Female; Fluorodeoxyglucose F18; Gallium Radioisotopes; Heat-Shock Proteins; Humans; Mice; Mice, Nude; Molecular Probes; Radiochemistry; Radiopharmaceuticals; Tissue Distribution; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2020
Preclinical PERCIST and 25% of SUV
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020, Volume: 61, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Fluorodeoxyglucose F18; Heterografts; Humans; Mice; Neoplasm Transplantation; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Triple Negative Breast Neoplasms

2020
    Breast cancer (Tokyo, Japan), 2020, Volume: 27, Issue:3

    Topics: Albendazole; Animals; Apoptosis; Cell Movement; Cell Proliferation; Female; Fluorodeoxyglucose F18; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Positron-Emission Tomography; Radiopharmaceuticals; Triple Negative Breast Neoplasms; Tubulin Modulators; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2020
SUV
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020, Volume: 61, Issue:9

    Topics: Breast Neoplasms; Fluorodeoxyglucose F18; Heterografts; Humans; Positron-Emission Tomography; Radiopharmaceuticals; Triple Negative Breast Neoplasms

2020
18F-fluorodeoxyglucose uptake on PET/computed tomography in association with androgen receptor expression and other clinicopathologic factors in surgically resected triple-negative breast cancer.
    Nuclear medicine communications, 2021, Volume: 42, Issue:1

    Topics: Adult; Aged; Biological Transport; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Positron Emission Tomography Computed Tomography; Receptors, Androgen; Triple Negative Breast Neoplasms

2021
In vivo selection of the MDA-MB-231br/eGFP cancer cell line to obtain a clinically relevant rat model for triple negative breast cancer brain metastasis.
    PloS one, 2020, Volume: 15, Issue:12

    Topics: Animals; Bone Neoplasms; Brain Neoplasms; Cell Line, Tumor; Female; Fluorodeoxyglucose F18; Green Fluorescent Proteins; Humans; Magnetic Resonance Imaging; Neoplasm Transplantation; Rats; Rats, Nude; Serial Passage; Triple Negative Breast Neoplasms

2020
Integrated analysis reveals the participation of IL4I1, ITGB7, and FUT7 in reshaping the TNBC immune microenvironment by targeting glycolysis.
    Annals of medicine, 2021, Volume: 53, Issue:1

    Topics: Fluorodeoxyglucose F18; Fucosyltransferases; Glucose; Glycolysis; Humans; Integrin beta Chains; L-Amino Acid Oxidase; Triple Negative Breast Neoplasms; Tumor Microenvironment

2021
GlucoCEST MRI for the Evaluation Response to Chemotherapeutic and Metabolic Treatments in a Murine Triple-Negative Breast Cancer: A Comparison with[
    Molecular imaging and biology, 2022, Volume: 24, Issue:1

    Topics: Animals; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Mice; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Triple Negative Breast Neoplasms

2022
Additional value of
    Cancer imaging : the official publication of the International Cancer Imaging Society, 2017, May-25, Volume: 17, Issue:1

    Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Triple Negative Breast Neoplasms

2017
Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from
    European journal of nuclear medicine and molecular imaging, 2017, Volume: 44, Issue:11

    Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Triple Negative Breast Neoplasms

2017
Noninvasive
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018, Volume: 59, Issue:1

    Topics: Animals; Biological Transport; Cell Line, Tumor; Cell Transformation, Neoplastic; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Mice; Positron-Emission Tomography; Proto-Oncogene Proteins c-myc; Radioisotopes; Transferrin; Triple Negative Breast Neoplasms; Zirconium

2018
Role of
    Clinical breast cancer, 2018, Volume: 18, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Postoperative Period; Predictive Value of Tests; Preoperative Period; Prognosis; Prospective Studies; Radiopharmaceuticals; Receptor, ErbB-2; ROC Curve; Triple Negative Breast Neoplasms

2018
Modulation of glutathione promotes apoptosis in triple-negative breast cancer cells.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2018, Volume: 32, Issue:5

    Topics: Animals; Buthionine Sulfoximine; Cell Line, Tumor; Deoxyuridine; DNA Breaks, Double-Stranded; Female; Fluorodeoxyglucose F18; Glutathione; Humans; Mice; Mice, Nude; Promoter Regions, Genetic; Reactive Oxygen Species; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2018
Early prediction of triple negative breast cancer response to cisplatin treatment using diffusion-weighted MRI and
    Breast cancer (Tokyo, Japan), 2018, Volume: 25, Issue:3

    Topics: Animals; Antineoplastic Agents; Breast; Cell Line, Tumor; Cisplatin; Diffusion Magnetic Resonance Imaging; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Multimodal Imaging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Survival Rate; Treatment Outcome; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2018
Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer.
    European journal of nuclear medicine and molecular imaging, 2018, Volume: 45, Issue:8

    Topics: Cell Proliferation; Fluorodeoxyglucose F18; Genomics; Humans; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Triple Negative Breast Neoplasms

2018
Now Is the Time to Use
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018, Volume: 59, Issue:6

    Topics: Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Triple Negative Breast Neoplasms

2018
[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer.
    PloS one, 2018, Volume: 13, Issue:5

    Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Cell Line, Tumor; Female; Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Mice; Mice, Nude; Mice, SCID; Neoadjuvant Therapy; Paclitaxel; Positron-Emission Tomography; Radiopharmaceuticals; ROC Curve; Thymidine; Transplantation, Heterologous; Triple Negative Breast Neoplasms

2018
Association between MRI Features and Standardized Uptake Value of 18F-FDG PET/CT in Triple-Negative Breast Cancer.
    Oncology research and treatment, 2018, Volume: 41, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Breast; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Triple Negative Breast Neoplasms

2018
Combination of breast imaging parameters obtained from
    European journal of radiology, 2019, Volume: 113

    Topics: Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fluorodeoxyglucose F18; Humans; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Retrospective Studies; ROC Curve; Tomography, X-Ray Computed; Triple Negative Breast Neoplasms

2019
FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
    Breast (Edinburgh, Scotland), 2013, Volume: 22, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Chemotherapy, Adjuvant; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Receptor, ErbB-2; Receptors, Estrogen; ROC Curve; Tomography, X-Ray Computed; Triple Negative Breast Neoplasms

2013
Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
    Breast (Edinburgh, Scotland), 2013, Volume: 22, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Carcinoma, Ductal, Breast; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Multimodal Imaging; Neoplasm Grading; Positron-Emission Tomography; Radiopharmaceuticals; ROC Curve; Triple Negative Breast Neoplasms

2013
Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy.
    European journal of nuclear medicine and molecular imaging, 2014, Volume: 41, Issue:1

    Topics: Adult; Aged; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Positron-Emission Tomography; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Sensitivity and Specificity; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Triple Negative Breast Neoplasms

2014
Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts.
    Acta oncologica (Stockholm, Sweden), 2013, Volume: 52, Issue:7

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Doxorubicin; Female; Fluorodeoxyglucose F18; Humans; Mice; Mice, Nude; Positron-Emission Tomography; Radiopharmaceuticals; Triple Negative Breast Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays

2013
Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve disease recurrence prediction in postmastectomy breast cancer patients with 1 to 3 positive axillary lymph nodes.
    International journal of radiation oncology, biology, physics, 2013, Nov-15, Volume: 87, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Axilla; Breast Neoplasms; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Positron-Emission Tomography; Postoperative Care; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Receptors, Estrogen; Risk Assessment; ROC Curve; Tomography, X-Ray Computed; Triple Negative Breast Neoplasms; Tumor Burden

2013
18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes.
    European radiology, 2014, Volume: 24, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Biopsy; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Retrospective Studies; Tomography, X-Ray Computed; Triple Negative Breast Neoplasms; Young Adult

2014
Relationship between tumor heterogeneity measured on FDG-PET/CT and pathological prognostic factors in invasive breast cancer.
    PloS one, 2014, Volume: 9, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Immunohistochemistry; Middle Aged; Multimodal Imaging; Multivariate Analysis; Neoplasm Invasiveness; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; ROC Curve; Tomography, X-Ray Computed; Triple Negative Breast Neoplasms

2014
Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Taxoids; Tomography, X-Ray Computed; Treatment Outcome; Triple Negative Breast Neoplasms

2014
Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer.
    European radiology, 2015, Volume: 25, Issue:11

    Topics: Adult; Aged; Carcinoma, Ductal, Breast; Female; Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed; Triple Negative Breast Neoplasms; Tumor Burden

2015
RECIST for Response (Clinical and Imaging) in Neoadjuvant Clinical Trials in Operable Breast Cancer.
    Journal of the National Cancer Institute. Monographs, 2015, Volume: 2015, Issue:51

    Topics: Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Mammography; Neoadjuvant Therapy; Positron-Emission Tomography; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Sensitivity and Specificity; Triple Negative Breast Neoplasms

2015
Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Dec-15, Volume: 21, Issue:24

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Biopsy; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Glucose; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Positron-Emission Tomography; Prognosis; ROC Curve; Tomography, X-Ray Computed; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Burden

2015
Variability of dynamic 18F-FDG-PET data in breast cancer xenografts.
    Acta oncologica (Stockholm, Sweden), 2015, Volume: 54, Issue:9

    Topics: Animals; Carcinoma, Ductal, Breast; Female; Fluorodeoxyglucose F18; Heterografts; Mammary Neoplasms, Experimental; Mice, Nude; Positron-Emission Tomography; Radiopharmaceuticals; Triple Negative Breast Neoplasms

2015
Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging.
    Breast cancer research and treatment, 2015, Volume: 153, Issue:3

    Topics: Adult; Aged; Biomarkers, Tumor; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Retrospective Studies; Tomography, X-Ray Computed; Triple Negative Breast Neoplasms; Tumor Burden

2015
¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016, Volume: 57, Issue:4

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Recurrence, Local; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Treatment Outcome; Triple Negative Breast Neoplasms

2016
(18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
    European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Early Detection of Cancer; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoplasm Staging; New York; Positron Emission Tomography Computed Tomography; Prevalence; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Survival Rate; Triple Negative Breast Neoplasms

2016
FDG-based quantitative comparison of glucose metabolism in vitro, exemplified by a head-to-head comparison between a triple-negative breast cancer cell line and a non-malignant foetal cell line.
    Clinical physiology and functional imaging, 2018, Volume: 38, Issue:1

    Topics: Adenosine Triphosphate; Cell Line, Tumor; Cell Proliferation; Culture Media, Conditioned; Energy Metabolism; Female; Fluorodeoxyglucose F18; HEK293 Cells; Humans; Hydrogen-Ion Concentration; Kidney; Lactic Acid; Radiopharmaceuticals; Time Factors; Triple Negative Breast Neoplasms; Tumor Hypoxia; Tumor Microenvironment

2018